Anatomical-Clinical Base of Adenocarcinoma Pancreatic
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: collection of biological samples.
- Who it may be relevant to
- Registry conditions: Adenocarcinoma, Carcinoma, Neoplasms. Basic parameters: 18 years — 120 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
BACAP-2 is a prospective biobank dedicated to the pancreatic adenocarcinoma including clinical data and biological samples from tumor. The aim is to enrich the previous propective collection BACAP in order to support future research projects.
Detailed description
Pancreatic cancer represents the fourth cause of death by cancer in Western countries. In over 90% of cases, it is due to an adenocarcinoma. The only curative treatment for pancreatic cancer remains the surgical exeresis. This one can only be suggested as a curative treatment in only 10 to 15% of cases. Besides, prevention or screening is difficult to set up due to the absence of clearly identified risk factors or groups and to the absence of useful markers for the diagnosis in clinical practice.
The research efforts in this area must face a double challenge: saving time while improving the diagnosis period and strengthen the therapeutic equipment. It is important to identify and characterise the new molecular markers applicable for a better diagnosis and/or treatment (especially the response factors to chemotherapy).
The present project aims to enrich with fresh tumor tissue and somatic genetic analysis the existing propective collection BACAP in order to support support future research projects on:
* the development of new diagnostic tools, * understanding the development of tumors of the pancreas * the development of new therapeutic targets * understanding the response to chemotherapy…
Interventions
- Other collection of biological samples
Collection of biological samples including whole blood and micro-biopsy from tissue of pancreas
Primary outcome measures
- Enrichment of prospective BACAP collection [Time frame: 5 years]
Eligibility criteria
Inclusion criteria
- Patient with pancreatic mass syndrome explored by ultrasound endoscopy with cytopuncture or
- Patient with pancreatic mass syndrome explored by an abdominal scanner with and without injection of product contrast and/or puncture of the mass or secondary lesions by radiological route or
- Patient with pancreatic adenocarcinoma proven histologically and/or cytologically
Exclusion criteria
- Patient with a pancreatic tumor whose analysis histological is not an adenocarcinoma
- Pregnant or breastfeeding patient
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Cohort
Study locations
France · 8 centers
- Béthune hospital center — Béthune
- Haut-Lévêque Hospital — Bordeaux
- Huriez Hospital — Lille
- Jean Mermoz private hosptila — Lyon
- Saint Eloi Hospital — Montpellier
- Regional Cancer Center From Montpellier — Montpellier
- PAU hospital — Pau
- Rangueil hospital — Toulouse
Publications
- Bardol T, Dujon AM, Taly V, Dunyach-Remy C, Lavigne JP, Costa-Silva B, Kurma K, Eslami-S Z, Cayrefourcq L, Canivet C, Muscari F, Bournet B, Alix-Panabieres C. Early detection of pancreatic cancer by liquid biopsy "PANLIPSY": a french nation-wide study project. BMC Cancer. 2024 Jun 10;24(1):709. doi: 10.1186/s12885-024-12463-8. PMID 38853244
Identifiers
NCT: NCT06128343 · RC31/21/0191 · 2021-A01050-41